1. Home
  2. CMRX

CMRX

Chimerix Inc.

Logo Chimerix Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.

Founded: 2000 Country:
United States
United States
Employees: N/A City: DURHAM
Market Cap: 85.7M IPO Year: 2013
Target Price: $8.00 AVG Volume (30 days): 422.4K
Analyst Decision: Strong Buy Number of Analysts: 3
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -0.93 EPS Growth: N/A
52 Week Low/High: $0.88 - $1.57 Next Earning Date: 05-02-2024
Revenue: $324,000 Revenue Growth: -99.04%
Revenue Growth (this year): 1526.54% Revenue Growth (next year): -58.52%

Share on Social Networks: